Trials / Not Yet Recruiting
Not Yet RecruitingNCT06459921
Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer
Efficacy and Safety of Neoadjuvant Sintilimab Puls FLOT Versus Sintilimab Puls SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the efficacy and safety of Sintilimab combined with FOLT versus Sintilimab combined with SOX in patients with locally advanced gastric cancer. The research design is intended to observe the comparison of conversion therapy effects, disease-free survival, R0 resection rate, and safety evaluation between the two groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOX+Sintilimab | Patients would be allocated to the SOX+Sintilimab group. |
| DRUG | FLOT+Sintilimab | Patients would be allocated to the FLOT+Sintilimab group. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2026-07-01
- Completion
- 2028-12-31
- First posted
- 2024-06-14
- Last updated
- 2024-10-10
Source: ClinicalTrials.gov record NCT06459921. Inclusion in this directory is not an endorsement.